Defining Iron And Haem-induced Pro-carcinogenic Pathways Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$566,277.00
Summary
Colorectal cancer is very common in Western society. Population studies have reported that high consumption iron-containing foods and red meat, the latter being a source of both haem and iron, are risk factors for colorectal cancer. This study will identify the levels of dietary haem and iron that promote colorectal cancer development. Also, it will determine the mechanisms and relative contribution of iron and haem to pro-carcinogenic pathways that result in colorectal cancer.
Overcoming Resistance To Anti-EGFR Antibody Therapy In Colorectal Cancer Using Novel Targeted PI3K And MEK Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$466,586.00
Summary
Cetuximab treatment is a standard of care for metastatic colorectal cancer, but patients with KRAS, BRAF, PIK3CA or PTEN gene mutated tumours show a lack of response. Newly developed targeted inhibitors against PI3K and MEK may overcome cetuximab resistance. We will perform preclinical studies in cell lines representing the range of mutated tumours found in patients to compare the efficacy of these novel treatments with cetuximab and to characterise the mechanisms underlying drug action.
Evaluation Of Blood-based Screening Tests For Colorectal Neoplasia; From Biomarker Candidates To Accurate And Acceptable Tests
Funder
National Health and Medical Research Council
Funding Amount
$767,382.00
Summary
Current bowel cancer screening tests require people to collect a stool sample. While able to be done at home, this creates certain inconveniences and has other barriers to its use including being distasteful to some. Also, even though stool tests are useful they are not as accurate as we would like. We have discovered a molecule in the blood of patients with bowel cancer that could, if configured as a screening test, serve to be of even greater accuracy and also be more acceptable to people.
Circulating Tumour DNA (ctDNA) As A Diagnostic Tool In Colorectal Cancer: Role In Screening And Early Detection Of Metastatic Or Recurrent Disease
Funder
National Health and Medical Research Council
Funding Amount
$500,478.00
Summary
These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to ....These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to save lives, will be greatly increased.Read moreRead less
Utilising Circulating Tumour DNA (ctDNA) To Optimise The Adjuvant Therapy And Follow-up Of Patients With Locally Advanced Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,316,682.00
Summary
The management of patients after surgery for rectal cancer presents multilpe dilemmas; what treatment should be given and to which patients? Our initial studies in colorectal cancer patients demonstrate that a novel blood biomarker (circulating tumour DNA) can accurately predict patient risk of recurrence and with serial samples, can indicate whether chemotherapy is being effective. During follow-up changes in this biomarker promise to be a specific and very early indicator of cancer recurrence.
KRAS- And BRAF-Mediated Methylation Signatures In Colorectal Cancers And Polyps
Funder
National Health and Medical Research Council
Funding Amount
$457,076.00
Summary
Bowel cancer is one of the most common cancers affecting Australians. We hypothesise that there are different types of bowel cancer depending on different genes that can be inactivated abnormally, and these subgroups have different clinical features and responses to therapy. We aim to identify the major gene changes that characterise these subgroups, which will in the future allow the development of gene markers for early detection as well as the possibility of individualised patient therapy.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
DNA Methylation As A Risk Factor For Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$780,185.00
Summary
Methylation of DNA involves a change to the chemical composition of DNA. It can affect the function of genes and normal methylation is essential for life. Aberrant methylation is associated with many diseases, including colorectal cancer. In this grant, we will explore whether aberrant methylation of DNA obtained from the blood can predict the risk of colorectal cancer. Our ultimate aim is to better identify people at higher risk of cancer.
About 14,000 cases of bowel cancer occur annually in Australia despite the availability of life-saving screening. Most people do not receive recommended screening colonoscopy. We will look at why people at high-risk avoid screening and why people at average risk seek unnecessary screening. We will analyse family history and contacts with the healthcare system that impact screening decisions. We will determine the impact of screening on reducing the number of new cases and deaths.
A La CaRT: Australasian Laparoscopic Cancer Of The Rectum Trial. A Phase III Prospective Randomised Trial Comparing Laparoscopic-assisted Resection Versus Open Resection For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$599,054.00
Summary
The major treatment for rectal cancer is surgical removal of tumour with a large cut through the abdomen. There is a newer, less invasive procedure known as laparoscopic resection which enables the same surgery to be performed using a scope inserted in the abdomen and another smaller incision for removal of the tumour. This study is being conducted to determine whether the newer procedure is as safe and effective as the current procedure. Patients on the trial will be given either laparoscopi